BFS
RGC icon

Bare Financial Services’s Regencell Bioscience RGC Stock Holding History

Bare Financial Services’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356 Buy
+14
New +$396 ﹤0.01% 1692

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bare Financial Services's RGC Position: Q1 2026 in Review

Bare Financial Services opened a new position in Regencell Bioscience (RGC) in Q1 2026: 14 shares worth $356. The stake represents ﹤0.01% of the portfolio and ranks #1692 among its holdings.

31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Bare Financial Services held 14 shares of Regencell Bioscience worth $356 as of Q1 2026.
  • Regencell Bioscience was a new Bare Financial Services position in Q1 2026.
  • Regencell Bioscience made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #1692 holding.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.